PRECISION BIOSCIENCES INC 8-K

What Happened Precision BioSciences, Inc. (DTIL) filed a Form 8‑K (Regulation FD disclosure) on March 17, 2026 to announce a live KOL webcast held that day at 9:00 a.m. ET. The event featured Aravindhan Veerapandiyan, MD (Pediatric Neurologist, Univ. of Arkansas for Medical Sciences and Arkansas Children’s Hospital) and Pat Furlong (Founding President, Parent Project Muscular Dystrophy), who joined company management to discuss the unmet need and current treatment landscape for Duchenne muscular dystrophy (DMD) and to provide an overview of the PBGENE‑DMD program and the FUNCTION‑DMD Phase 1/2 clinical trial. The event presentation was furnished as Exhibit 99.1 and is available on the company’s investor website under Events & Presentations.

Key Details

• Event date & time: March 17, 2026 at 9:00 a.m. Eastern Time (live webcast).
• Speakers: Aravindhan Veerapandiyan, MD, and Pat Furlong, plus Precision BioSciences management.
• Topics: Unmet need and treatment landscape for DMD; overview of PBGENE‑DMD program and FUNCTION‑DMD Phase 1/2 trial.
• Materials: Presentation furnished as Exhibit 99.1 to the 8‑K and accessible at https://investor.precisionbiosciences.com/events-and-presentations. Report signed by CFO John Alexander Kelly.

Why It Matters This Regulation FD disclosure publicly distributes company communications about its DMD gene‑editing program, making management and KOL commentary and presentation materials available to all investors at the same time. For investors, the webcast and the furnished presentation are key sources of program-level updates and context on the PBGENE‑DMD development strategy and the FUNCTION‑DMD Phase 1/2 trial, which could inform expectations about next clinical milestones and timelines. Review the posted presentation for specifics on trial design, endpoints, or planned next steps.